Incyte Insider Sales, Stock Rally and New Approvals
Key Points
- Incyte shares have climbed nearly 50% in six months amid strong results
- Principal accounting officer Tray Thomas disclosed stock sales totaling 3,374 shares
- Japan and EU approvals for Minjuvi and Zynyz expand Incyte’s oncology reach
- Analysts see solid earnings growth but maintain a consensus Hold rating
Insider Tray Thomas Trims Stake While Retaining Large Holding
Incyte Corporation’s principal accounting officer, identified in some filings as Tray Thomas and in others as Thomas Tray, has reported a series of insider transactions in December. According to SEC disclosures, he sold a total of 3,374 Incyte shares across December 18 and 19 at prices around $98 to $100 per share, for aggregate proceeds of roughly $336,350. One MarketBeat report notes that the 2,774‑share sale on December 19 alone represented a 10.77% reduction in his ownership. At the same time, Investing.com reports that Thomas also acquired 2,774 shares through stock option exercises worth about $265,638. Following these transactions, he directly owns 22,973 shares of the biopharmaceutical company, a stake valued at more than $2.25 million based on recent trading prices. The insider activity comes alongside reports that another Incyte executive vice president sold about $5.25 million of stock, contributing to a cluster of insider selling highlighted in recent coverage.
Share Price Momentum and Recent Trading Performance
Incyte’s stock has shown notable strength in recent months. Investing.com reports that the shares have risen 49.7% over the past six months, while Nasdaq notes a 5.5% gain in the most recent trading session, with the stock closing at $102.69 on heavy volume. MarketBeat data show the shares trading at $100.71 in Monday’s session, with a one‑year range between $53.56 and $109.28. The company’s market capitalization stands at $19.77 billion, with a price‑to‑earnings ratio of 16.87, a price‑to‑earnings‑growth ratio of 0.70 and a beta of 0.81. Incyte’s 50‑day moving average is reported at $98.53, above its 200‑day moving average of $85.09, reflecting the recent uptrend. A Zacks note cited by MarketBeat and Nasdaq flagged the recent rally and above‑average trading volume, while cautioning that unchanged earnings estimate revisions could limit near‑term upside.
Earnings Strength and Financial Profile
The company’s recent financial results have underpinned investor interest. Incyte reported quarterly earnings per share of $2.26 on October 28, beating the consensus estimate of $1.65 by $0.61. Revenue for the quarter was $1.37 billion, ahead of analyst expectations of $1.26 billion and up 20% from the same period a year earlier. Net margin was 24.69%, and return on equity reached 26.56%. The company’s balance sheet metrics include a quick ratio of 3.13, a current ratio of 3.20 and a debt‑to‑equity ratio of 0.01, which Investing.com and MarketBeat describe as indicators of strong financial health. Analysts tracked by MarketBeat expect Incyte to post full‑year earnings of 4.86 per share. Separately, Nasdaq reports that Incyte is expected to deliver upcoming quarterly EPS of $1.96, a 37.1% year‑over‑year increase, on revenue of $1.35 billion, up 14.4% from the prior‑year quarter.
Regulatory Wins Expand Oncology Portfolio
Recent regulatory decisions have broadened Incyte’s commercial footprint in oncology. MarketBeat highlights that Japan has approved Zynyz (retifanlimab) for first‑line treatment of advanced anal cancer. In addition, Japan approved Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma. Investing.com and Investing.com India also report that the European Commission has approved Minjuvi for specific lymphoma treatment. These approvals add to Incyte’s portfolio of marketed therapies across hematology, dermatology and oncology, which includes its flagship product Jakafi (ruxolitinib) for myelofibrosis and polycythemia vera. Coverage characterizes these regulatory wins as supportive of additional revenue and market expansion in major markets.
Analyst Ratings, Institutional Ownership and Outlook
Analyst sentiment toward Incyte remains mixed but generally constructive. MarketBeat data show eight analysts rating the stock Buy, eleven rating it Hold and one assigning a Sell rating, resulting in a consensus Hold and an average price target of $99.07. Recent target price increases include Barclays lifting its target to $115 with an Overweight rating, Stifel Nicolaus raising its objective to $115 with a Buy rating, and Mizuho setting a $121 target with an Outperform rating. Other firms such as Royal Bank of Canada and Piper Sandler have also raised their price objectives while assigning sector perform or overweight ratings. Nasdaq notes that Zacks currently assigns Incyte a Rank #3 (Hold). Institutional investors hold a dominant position in the stock, with MarketBeat reporting that hedge funds and other institutions own 96.97% of shares. Recent activity includes increased stakes by firms such as Swiss Life Asset Management, Groupama Asset Management and CIBC‑affiliated entities, alongside smaller position changes by other investors.
Key Takeaways
- Insider selling by Incyte’s principal accounting officer and an EVP has occurred against a backdrop of strong share price gains and robust fundamentals.
- The stock’s nearly 50% six‑month rise, supported by earnings beats and revenue growth, has pushed valuation higher while analysts broadly maintain Hold ratings.
- New approvals for Minjuvi and Zynyz in Japan and Europe extend Incyte’s oncology reach and are seen in coverage as supportive of future revenue expansion.
References
- 1. https://www.marketbeat.com/instant-alerts/incyte-nasdaqincy-insider-sells-27740000-in-stock-2025-12-22/
- 2. https://in.investing.com/news/insider-trading-news/incyte-principal-accounting-officer-tray-thomas-sells-shares-worth-336k-93CH-5164027
- 3. https://www.nasdaq.com/articles/incyte-incy-soars-55-further-upside-left-stock
- 4. https://www.investing.com/news/insider-trading-news/incyte-principal-accounting-officer-tray-thomas-sells-shares-worth-336k-93CH-4420492
Get premium market insights delivered directly to your inbox.